R&D channel feed

Twist Bio­science lays off 212 staffers, most­ly in San Fran­cis­co

Last year

FDA ap­proves Roche’s sec­ond CD20xCD3 bis­pe­cif­ic in cer­tain lym­phomas

Last year
Pharma

FDA de­lays de­ci­sion on GSK blood can­cer drug at heart of $1.9B Sier­ra On­col­o­gy deal

Last year
Pharma

Prime Med­i­cine con­sid­ers fo­cus on au­toim­mune dis­eases for CAR-T, CEO says

Last year
Cell/Gene Tx

Corvus touts ear­ly da­ta on T cell lym­phoma drug, makes PhI­II plans

Last year

Mer­sana slapped with par­tial FDA hold af­ter five pa­tient deaths in ovar­i­an can­cer stud­ies

Last year
FDA+

To sN­DA or NDA? Aldeyra clears a sec­ond PhI­II for sea­son­al al­ler­gy eye drop

Last year

'Mod­er­na will be a rare dis­ease com­pa­ny,' CEO says, as mR­NA com­pa­ny plots ex­pan­sion in ge­net­ic dis­eases and eyes n-of-1 treat­ments

Last year
Pharma
In Focus

Pfiz­er re­files Seagen ac­qui­si­tion pa­per­work, deal still ex­pect­ed to close with­in the year

Last year

Three chil­dren with leukemia treat­ed with first base-edit­ed cell ther­a­py; one died from in­fec­tion

Last year

Ku­ra plans to sell $100M of shares on the back of in­ter­im read­out of acute myeloid leukemia drug

Last year

Ax­some re­ports de­lay to PhI­II nar­colep­sy study, un­veils peak sales es­ti­mates on its drugs

Last year

Pa­tient death leads Seat­tle Chil­dren’s to pause study of 2sev­en­ty bio’s CAR-T cell ther­a­py 

Last year
Cell/Gene Tx

Gavi re­ports 're­bound' year for child­hood vac­ci­na­tions

Last year

FDA ad watch­dog sends first rep­ri­mand of 2023 to Xeris over ‘mis­lead­ing’ drug claims

Last year

Al­ladapt touts da­ta on food al­ler­gy drug as it preps for PhI­II

Last year

Ex­clu­sive: Bat­tle with ‘un­drug­gable’ can­cer tar­get be­ta-catenin heats up, as Sapi­ence dos­es first pa­tient

Last year

Scoop: In­Car­da ter­mi­nates its PhI­II tri­al for ar­rhyth­mia drug that was cen­tral to plans for an IPO

Last year

In­tel­lia’s sec­ond CRISPR ther­a­py re­duces swelling at­tacks by 95% in hered­i­tary an­gioede­ma

Last year

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Last year

FDA wants more da­ta from Abeona Ther­a­peu­tics as it push­es for BLA

Last year
Cell/Gene Tx
Manufacturing

Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

Last year
Financing
Startups

Disc Med­i­cine claims PhII win for re­pur­posed ex-Roche drug in rare blood dis­or­der

Last year

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

Last year
First page Previous page 82838485868788 Next page Last page
A service from the Financial Times